Risk of proarrhythmic events in the atrial fibrillation follow-up investigation of rhythm management (AFFIRM) study: A multivariate analysis

Journal of the American College of Cardiology

Volumn 44, Issue 6, 2004, Pages 1276-1282

  Kaufman, Elizabeth S ^a,f   Zimmermann, Paul A ^b   Wang, Ted ^c   Dennish III, George W ^d   Barrell, Patrick D ^e   Chandler, Mary L ^e   Greene, H Leon ^e  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b South Carolina Heart Center   (United States)

^c ADVOCATE ILLINOIS MASONIC MEDICAL CENTER   (United States)

^d SCRIPPS MEMORIAL HOSPITAL   (United States)

^e Axio Research Corporation   (United States)

^f Heart and Vascular Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIARRHYTHMIC AGENT;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG SAFETY; EXPOSURE; FEMALE; FOLLOW UP; HEART ARREST; HEART ATRIUM FIBRILLATION; HEART DEATH; HEART LEFT VENTRICLE EJECTION FRACTION; HEART PROARRHYTHMIA; HEART VENTRICLE TACHYCARDIA; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL COMPUTING; MEDICAL DOCUMENTATION; PATIENT SELECTION; PRIORITY JOURNAL; RESUSCITATION; SIDE EFFECT; STATISTICAL SIGNIFICANCE; TORSADE DES POINTES; TREATMENT OUTCOME;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; CIRCADIAN RHYTHM; FEMALE; FOLLOW-UP STUDIES; HEART RATE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RISK FACTORS; SEX FACTORS; STROKE VOLUME; SURVIVAL RATE; TACHYCARDIA, VENTRICULAR; TREATMENT OUTCOME;

EID: 4444277300     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2004.06.052     Document Type: Article

References (33)

1. P.J. Podrid, S. Lampert, T.B. Graboys, C.M. Blatt, B. Lown Aggravation of arrhythmia by antiarrhythmic drugsincidence and predictors Am J Cardiol 59 1987 38E 44E
2. J. Morganroth Early and late proarrhythmia from antiarrhythmic drug therapy Cardiovasc Drugs Ther 6 1992 11 14
3. M.S. Stanton, E.N. Prystowsky, N.S. Fineberg, W.M. Miles, D.P. Zipes, J.J. Heger Arrhythmogenic effects of antiarrhythmic drugs: a study of 506 patients treated for ventricular tachycardia or fibrillation J Am Coll Cardiol 14 1989 209 215
4. D.M. Roden, R.L. Woosley, P.K. Primm Incidence and clinical features of the quinidine-associated long QT syndrome: implications for patient care Am Heart J 111 1986 1088 1093
5. D.S. Echt, P.R. Liebson, L.B Mitchell Mortality and morbidity in patients receiving encainide, flecainide, or placebo The Cardiac Arrhythmia Suppression Trial N Engl J Med 324 1991 781 788
6. P.P. Sharma, P. Ott, V. Hartz, J.W. Mason, F.I. Marcus Risk factors for tachycardia events caused by antiarrhythmic drugs: experience from the ESVEM trial J Cardiovasc Pharmacol Therapeut 3 1998 269 274
7. The Planning and Steering Committees of the AFFIRM Study for the NHLBI AFFIRM Investigators Atrial fibrillation follow-up investigation of rhythm managementthe AFFIRM study design Am J Cardiol 79 1997 1198 1202
8. The AFFIRM Investigators Baseline characteristics of patients with atrial fibrillationthe AFFIRM study Am Heart J 143 2002 991 991001
9. The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators A comparison of rate control and rhythm control in patients with atrial fibrillation N Engl J Med 347 2002 1825 1833
10. P.M. Rautaharju, S.H. Zhou, S Wong Sex differences in the evolution of the electrocardiographic QT interval with age Can J Cardiol 8 1992 690 695
11. R.E. Benton, M. Sale, D.A. Flockhart, R.L. Woosley Greater quinidine-induced QTc interval prolongation in women Clin Pharmacol Ther 67 2000 413 418
12. R.R. Makkar, B.S. Fromm, R.T. Steinman, M.D. Meissner, M.H. Lehmann Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs JAMA 270 1993 2590 2597
13. M.H. Lehmann, S. Hardy, D. Archibald, B. Quart, D.J. MacNeil Sex difference in risk of torsade de pointes with sotalol Circulation 94 1996 2535 2541
14. B.S. Stambler, M.H. Wood, K.A. Ellenbogen, K.T. Perry, L.K. Wakefield, J.T. VanderLugt Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation Circulation 94 1996 1613 1621
15. E.M. Vaughan Williams Classification of antiarrhythmic drugs E. Sande E. Flensted-Jensen E.H. Olsen Symposium on Cardiac Arrhythmias 1970 AB Astra Stdertlje, Sweden 449 501
16. D.C. Harrison Symposium on perspectives on treatment of ventricular arrhythmias: introduction Am J Cardiol 52 1983 1C 2C
17. J.L. Anderson, E.V. Platia, A Hallstrom Interaction of baseline characteristics with the hazard of encainide, flecainide, and moricizine therapy in patients with myocardial infarction A possible explanation for increased mortality in the Cardiac Arrhythmia Suppression Trial (CAST) Circulation 90 1994 2843 2852
18. G.C. Flaker, J.L. Blackshear, R. McBride, R.A. Kronmal, J.L. Halperin, R.G. Hart Stroke Prevention in Atrial Fibrillation Investigators Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation J Am Coll Cardiol 290 1992 527 532
19. J.S. Steinberg, A. Sadaniantz, J Kron Analysis of cause-specific mortality in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) trial Circulation 109 2004 1973 1980
20. R. Rokseth, O. Storstein Quinidine therapy of chronic auricular fibrillation Arch Intern Med 111 1963 184 189
21. M.D. Radford, D.W. Evans Long term results of DC reversion of atrial fibrillation Br Heart J 30 1968 91 96
22. T. Sodermark, B. Jonsson, A Olsson Effect of quinidine on maintaining sinus rhythm after conversion of atrial fibrillation or flutter Br Heart J 37 1975 486 492
23. B. Lown, M. Wolf Approaches to sudden death from coronary heart disease Circulation 44 1971 130 142
24. S.E. Coplen, E.M. Antman, J.A. Berlin, P. Hewitt, T.C. Chalmers Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion Circulation 82 1990 1106 1116
25. S.C. Reimold, T.C. Chalmers, J.A. Berlin, E.M. Antman Assessment of the efficacy and safety of antiarrhythmic therapy for chronic atrial fibrillation Am Heart J 124 1992 924 932
26. The CAST Investigators Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction N Engl J Med 321 1989 406 412
27. D.S. Echt, P.R. Liebson, L.B. Mitchell CAST Investigators Mortality and morbidity in patients receiving encainide, flecainide, or placebo N Engl J Med 324 1991 781 788
28. S.H. Hohnloser, W. Arendts, B. Quart Torsade de pointes during sotalol therapy (abstr) Eur Heart J 13 Suppl 1992 305
29. M.H. Lehmann, S. Hardy, D. Archibald, B. Quart, D.J. MacNeil Sex difference in risk of torsades de pointes with d,l-sotalol Circulation 94 1996 2534 2541
30. Tikosyn [package insert]. New York, NY: Pfizer Labs, 1999.
31. D. Wolbrette, G. Naccarelli, A. Curtis, M. Lehmann, A. Kadish Gender differences in arrhythmias Clin Cardiol 25 2002 49 56
32. I.C. Van Gelder, V.E. Hagens, H.A Bosker Rate Control versus Electrical Cardioversion for Persistent Atrial Fibrillation Study Group A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation N Engl J Med 347 2002 1834 1840
33. J.T. Bigger, J.L. Fleiss, R. Kleiger, J.P. Miller, L.M. Rolnitzky The Multicenter Post Infarction Program: the relationship between ventricular arrhythmias, left ventricular dysfunction and mortality in the years after myocardial infarction Circulation 69 1984 250 258